newsfilter
← Earnings
Earnings Releases·

Zai Lab — Third Quarter 2026 Earnings Summary

Zai Lab reported third-quarter 2026 total revenues of $108.2 million, reflecting a 2% sequential increase in net product revenue driven by NUZYRA and the June 2026 launch of KarXT. The company announced compelling first-line small cell lung cancer data for its zoci plus atezolizumab combination, showing an 81.8% confirmed objective response rate and advancing toward a global Phase 3 study. Zai Lab completed a private placement in October 2026, raising approximately $241.2 million in net proceeds to fund pipeline development and working capital. Key pipeline milestones include expected data readouts for zoci in second-line extrapulmonary neuroendocrine carcinomas and initial clinical data for the ZL-1503 atopic dermatitis program in the first half of 2027.

Company
ZAI LAB LTD
Sector
Healthcare
Industry
Biotechnology